LXRX
HealthcareLexicon Pharmaceuticals, Inc.
$1.14
+$0.00 (+0.00%)
Jan 5, 2026
Price History (1Y)
Analysis
Lexicon Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector, with a market capitalization of $414.27 million. The company has 103 employees and operates within the broader context of the biotechnology industry. Financially, Lexicon Pharmaceuticals reported revenue of $70.86 million for the trailing twelve months (TTM), but incurred significant losses, including net income of -$68,577,000 and EBITDA of -$53,940,000. The company's gross margin was -7.0%, operating margin was -85.9%, and profit margin was -96.8%. In terms of returns, Lexicon Pharmaceuticals reported a return on equity (ROE) of -45.9% and a return on assets (ROA) of -12.9%. The company's balance sheet shows debt of $64.95 million and cash reserves of $115.95 million. The valuation metrics for Lexicon Pharmaceuticals are notable, with a forward price-to-earnings ratio of -4.39 and an earnings growth rate that is not available (N/A). Additionally, the company's revenue has grown by 710.4% year-over-year (YoY), but this significant increase in revenue does not appear to have translated into improved profitability.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Visit website →Key Statistics
- Market Cap
- $414.27M
- P/E Ratio
- N/A
- 52-Week High
- $1.66
- 52-Week Low
- $0.28
- Avg Volume
- 2.05M
- Beta
- 0.72
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 103